Before the CAR arrives: how neuro-oncological treatment history shapes CAR-T cell therapy in brain tumors

Chimeric antigen receptor (CAR) T-cell therapy has shown clear biological activity in brain tumors, yet durable responses remain uncommon. Most studies have focused on CAR design, target selection and route of delivery, whereas the biological consequences of treatments administered before CAR-T infusion have received less attention. In neuro-oncology, however, CAR-T cells rarely encounter an untreated tumor. Surgery, radiotherapy, temozolomide, corticosteroids, anti-VEGF therapy and disease progression can reshape antigen expression, vascular access, myeloid composition, lymphocyte fitness and systemic immune competence. These effects may either create transient therapeutic opportunities or generate additional barriers to cellular therapy. Evidence from glioblastoma illustrates how surgery, chemoradiotherapy and recurrence progressively remodel the tumor-host ecosystem, while emerging pediatric data extend this concept beyond glioma. In diffuse midline glioma, early-phase trials have positioned CAR-T therapy after upfront radiotherapy and before or around progression. In medulloblastoma, craniospinal irradiation can produce profound lymphopenia, FLASH radiotherapy can modify macrophage states and sensitize tumors to GD2-directed CAR-T cells, and pharmacological modulation of GD2 expression can alter CAR susceptibility. Preclinical and early clinical studies in medulloblastoma and ependymoma further support locoregional delivery and histology-specific target selection. We therefore propose that treatment history should be considered a biological variable in CAR-T trial design rather than a descriptive baseline characteristic. Prospective studies should reconstruct prior treatment exposure, reassess target expression, measure immune recovery and define histology-specific windows in which tumor burden, antigen availability, tissue access and T-cell fitness are most favorable for CAR-T activity. This framework may help explain heterogeneous outcomes across current brain-tumor trials.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1980506
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Before the CAR arrives: how neuro-oncological treatment history shapes CAR-T cell therapy in brain tumors

Giada Del Baldo, Angela Mastronuzzi, Andrea Carai
1 links
Frontiers in Immunology
CAR-T cell therapy research
article

Before the CAR arrives: how neuro-oncological treatment history shapes CAR-T cell therapy in brain tumors

Giada Del Baldo, Angela Mastronuzzi, Andrea Carai
article en

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has shown clear biological activity in brain tumors, yet durable responses remain uncommon. Most studies have focused on CAR design, target selection and route of delivery, whereas the biological consequences of treatments administered before CAR-T infusion have received less attention. In neuro-oncology, however, CAR-T cells rarely encounter an untreated tumor. Surgery, radiotherapy, temozolomide, corticosteroids, anti-VEGF therapy and disease progression can reshape antigen expression, vascular access, myeloid composition, lymphocyte fitness and systemic immune competence. These effects may either create transient therapeutic opportunities or generate additional barriers to cellular therapy. Evidence from glioblastoma illustrates how surgery, chemoradiotherapy and recurrence progressively remodel the tumor-host ecosystem, while emerging pediatric data extend this concept beyond glioma. In diffuse midline glioma, early-phase trials have positioned CAR-T therapy after upfront radiotherapy and before or around progression. In medulloblastoma, craniospinal irradiation can produce profound lymphopenia, FLASH radiotherapy can modify macrophage states and sensitize tumors to GD2-directed CAR-T cells, and pharmacological modulation of GD2 expression can alter CAR susceptibility. Preclinical and early clinical studies in medulloblastoma and ependymoma further support locoregional delivery and histology-specific target selection. We therefore propose that treatment history should be considered a biological variable in CAR-T trial design rather than a descriptive baseline characteristic. Prospective studies should reconstruct prior treatment exposure, reassess target expression, measure immune recovery and define histology-specific windows in which tumor burden, antigen availability, tissue access and T-cell fitness are most favorable for CAR-T activity. This framework may help explain heterogeneous outcomes across current brain-tumor trials.

Frontiers in ImmunologyVol. 17
Università Cattolica del Sacro Cuore (IT), Bambino Gesù Children's Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon